Protective Effects of *Caesalpinia sappan* Linn. and Its Bioactive Compounds on Cardiovascular Organs

**Mas Rizky AA Syamsunarno¹, Ratu Safitri² and Yusof Kamisah³*¹**

¹Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Jatinangor, Indonesia, ²Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jatinangor, Indonesia, ³Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

Cardiovascular diseases are the leading cause of death worldwide. The long-term aim of cardiovascular disease therapy is to reduce the mortality rate and decelerate the progression of cardiovascular organ damage. Current therapies focus on recovering heart function and reducing risk factors such as hyperglycemia and dyslipidemia. However, oxidative stress and inflammation are important causes of further damage to cardiovascular organs. *Caesalpinia sappan* Linn. (Fabaceae), a flowering tree native to tropical Asia, has antioxidant and anti-inflammatory properties. It is used as a natural dye to color food and beverages and as a traditional treatment for diarrhea, diabetes, and blood stasis. The phytochemical compounds in *C. sappan*, mainly the homoisoflavonoids brazilin, sappanone A, protosappanin, and hematoxylin, can potentially be used to protect cardiovascular organs. This review aims to provide updates on recent developments in research on *C. sappan* in relation to treatment of cardiovascular diseases. Many studies have reported protective effects of the plant’s bioactive compounds that reduce cardiac damage and enhance vasorelaxation. For example, brazilin and sappanone A have an impact on molecular and cellular changes in cardiovascular disease pathogenesis, mainly by modulating oxidative, inflammatory, and apoptotic signaling pathways. Therefore, bioactive compounds of *C. sappan* have the potential to be developed as therapeutic agents to combat cardiovascular diseases like myocardial infarction and vascular disease. This review could help further the understanding of the possible modulatory role of the compounds in cardiovascular diseases, thereby facilitating future studies.

**Keywords:** *Caesalpinia sappan*, brazilin, sappanone A, brazilein, ischemia/reperfusion injury, vasorelaxation, heart, vascular

**INTRODUCTION**

Cardiovascular disease is a leading cause of morbidity and mortality globally, with heart attack and stroke accounting for about 85% of these deaths, the majority occurring in middle- and low-income countries (WHO, 2017). Cardiovascular disease includes disorders of the heart and blood vessels, such as ischemic heart attack or myocardial infarction, heart failure, hypertension, and cerebrovascular disease (Leong et al., 2017). The pathogenesis of these disorders involves oxidative stress and inflammation (Siti et al., 2015).
Therefore, intervention with medicinal plants possessing antioxidant and anti-inflammatory properties may alleviate the severity of the disease. Numerous studies have investigated medicinal plants for their potential pharmacological activities in cardiovascular organs, and many have shown promising effects. *Parkia speciosa* Hassk. alleviated cardiac damage in hypertensive rats (Kamisah et al., 2017), *Hibiscus sabdariffa* L. showed cardioprotective effects in myocardial infarction-induced rats (Si et al., 2019), and *Caesalpinia sappan* Linn. extract demonstrated a vasorelaxant effect on rat arteries (Sasaki et al., 2010).

*Caesalpinia sappan* is a medicinal plant that possesses antioxidant (Suwan et al., 2018) and anti-inflammatory (Tewtrakul et al., 2015) properties. It exerts protective effects on the cardiac (Nugraheni and Saputri, 2017) and vascular (Sasaki et al., 2010) systems. Investigations of this plant have progressed to isolation of the active metabolites, such as brazilin, sappanchalcone, and protosapapann D (Sasaki et al., 2010), that might be responsible for the protective effects, but these studies are still at the initial phase. Therefore, this review aims to gather information on recent updates to studies on *C. sappan* extract and the effects of its metabolites on cardiovascular organs. Our findings could accelerate future research on the plant and the development of its metabolites as alternatives to modern medicine.

**CAESALPINIA SAPPAN AND ITS BIOACTIVE METABOLITES**

*Caesalpinia sappan* Linn. (synonymous with *Biancaea sappan*), commonly known as sappanwood, grows abundantly in Southeast Asia, southern China (Li et al., 2020) and the Indian subcontinent, either in the wild or as a cultivated tree (Mariappan et al., 2014). It is known locally as secang or sekang in Indonesia, *pokok se pang* in Malaysia (Nugraheni and Saputri, 2017), and pattanga in India (Chellappan et al., 2017). The plant belongs to the family Fabaceae (subfamily Caesalpinioideae), and is a shrubby tree that grows to 10 m tall, with a ca. 14 cm diameter trunk and alternate bipinnate leaves (Mariappan et al., 2014). It bears clusters of flat, oblong pods that contain brown flattened and ellipsoid seeds (Warriers et al., 1993). Its wood is hard and orange red. Its heartwood has been traditionally used to treat bleeding gums, anemia, diabetes, cardiac problem and blood stasis and as a post-partum tonic to reduce uterine bleeding; it is also known for its antidiarrheal, sedative, and blood stasis and as a post-partum tonic to reduce uterine diseases (Do, 2001). It is also an ingredient in several Ayurvedic preparations (Mekala and Radha, 2015).

Many bioactive compounds have been isolated from *C. sappan*. Some of the most abundant phytochemicals present in the plant are homoisoflavonoids, of which brazilin—a natural red dye—is the major active compound (Settharaksa et al., 2019; Uddin et al., 2015), along with its oxidized form, brazilein (Dapson and Bain, 2015), in the heartwood. Other homoisoflavonoids present in the plant are sappanol, episappanol, protosapapann B and C (Mueller et al., 2016; Uddin et al., 2015), *caesapinn A and B* (Wang et al., 2014), sappanone A (Zhao et al., 2020), sappanone B, (E)-3-(3,4-dihydroxybenzylidene)-7-hydroxyxchroman-4-one (He et al., 2009), deoxysappapann B (Zeng et al., 2015), neoessapanone A, neoeprosapapann (Nguyen et al., 2005), and caesalpin P and J (Shimokawa et al., 1985) (Table 1). The chemical structures of the key metabolites in *C. sappan* are presented in Figure 1. These homoisoflavonoids have antioxidant (Uddin et al., 2015), antibacterial (Settharaksa et al., 2019), anti-inflammatory (Choo et al., 2017) and neuroprotective (Zeng et al., 2015) properties. The heartwood also contains the following phenols: caesalpinaphenol A–H (Cuong et al., 2012; Min et al., 2012; Hung et al., 2013), epicaesapinn J, and 7,10,11-trihydroxydracaenaone (Zhao et al., 2014). The latter two compounds do not show significant inhibitory activity against nitric oxide (Zhao et al., 2014), a vasodilator found in blood vessels. The seeds of *C. sappan* are rich in diterpenoids, including caesalsapapann A–N, R and S (Ma et al., 2015; Bao et al., 2016; Zhu et al., 2017; Wang et al., 2020); phanginin A–K and R–T (Yodsaoue et al., 2008; Bao et al., 2016); and ester glycosides, namely caesateroside A–C (Wang et al., 2020). Oleonolic acid, a triterpenoid, has also been isolated from the plant (Zheng et al., 2020). These diterpenoids exhibit antiplasmodial (Zhu et al., 2017) and antitumor (Bao et al., 2016; Wang et al., 2020) activity.

**PHARMACOKINETICS AND TOXICITY OF CAESALPINIA SAPPAN AND ITS BIOACTIVE COMPOUNDS**

**Pharmacokinetics**

Studies on the pharmacokinetic properties of the *C. sappan* metabolites are still lacking. Only brazilin has been studied extensively. Oral and intravenous administration of brazilin resulted in the incorporation of a similar amount of the phytochemical into the plasma (Jia et al., 2013), indicating its almost complete oral absorption. When brazilin was injected into the tail vein of rats at 50 mg/kg body weight, the plasma area under the curve (AUC) showed that it was absorbed at approximately 1,500 ng h/mL. It has a half-life (*t*<sub>1/2</sub>) of 4.4 h, a peak plasma concentration (C<sub>max</sub>) of approximately 1,600 ng/ml, and a time to reach maximum concentration (T<sub>max</sub>) of approximately 2 min (Jia et al., 2013), which suggests a rapid absorption process. Brazilin also demonstrated linear pharmacokinetics in rats, according to the C<sub>max</sub> and AUC values, which increased with increasing dosage (Yan-yan et al., 2014). On the other hand, when *C. sappan* extract that contained 52.25 mg/kg of brazilin was orally administered at 2.83 g/kg body weight, a similar AUC was observed, but the T<sub>max</sub> was tenfold longer and the *t*<sub>1/2</sub> was shorter (2.21 h) (Tong et al., 2013) than that of brazilin in a previous study (Jia et al., 2013). This may have been due to other bioactive compounds present in the extract affecting the absorption and/or elimination of brazilin. The compound was dispersed into almost all organs, with the highest concentrations found in the kidneys, followed by the liver and lungs (Jia et al., 2013).
Oral administration of *C. sappan* extract (at 2.83 g/kg body weight) that contained 35.56 mg/kg protosappanin B resulted in a $t_{\text{max}}$ and a $T_{\text{max}}$ similar to those of brazilein (Tong et al., 2013). Diabetes affected the pharmacokinetics of protosappanin B and brazilein similarly, observed as augmentation of $C_{\text{max}}$, AUC, and $t_{\text{max}}$. However, diabetes reduced the $T_{\text{max}}$ of protosappanin B, but did not affect that of brazilein (Tong et al., 2013). Taken together, these results suggest that brazilein has an almost complete and fast oral absorption as well as distribution. This property makes the compound a promising candidate for further study.

**Toxicity**

A single oral dose of *C. sappan* at 5,000 mg/kg body weight, and repeated at doses of 250, 500 and 1,000 mg/kg for 30 days yielded no toxic effects in male and female Wistar rats. No apparent changes in body weight, the gross appearance of internal organs—the heart, liver, brain, lungs, pancreas, spleen, adrenal glands, kidneys, and sex organs—or general behavior were noted compared to control (Sireeratawong et al., 2016). These findings suggest that brazilein should be taken with caution by pregnant women, as it may have a significant impact on embryo development and growth after implantation.

**EFFECTS ON MYOCARDIAL INJURY**

**Caesalpinia sappan** Extract

Only one study to date (Nugraheni and Saputri, 2017) investigated the effects of *C. sappan* crude extract using a...
myocardial injury model. However, the plant taxonomy could not be confirmed as it was not validated by a botanist. The study investigated the preventive effect of oral *C. sappan* extract as claimed, at doses of 50, 100, and 200 mg/kg for 30 days on isoproterenol-induced myocardial infarction in rats (Table 2). The extract did not reverse the increase in heart weight induced by isoproterenol. However, qualitative observations of the heart infarct area suggested that the extract reduced size or the area with increasing doses. Histologically, the extract significantly reduced myocardial interstitial edema at all experimental doses, and the severity of myocardial necrosis and inflammatory cell infiltration was significantly alleviated at 100 and 200 mg/kg doses of the extract (Nugraheni and Saputri, 2017). These findings demonstrate potential positive effects of *C. sappan* extract that protect against myocardial injury, likely afforded by the presence of bioactive compounds in the extract that was unfortunately not determined in the study. However, in terms of experimental design, the study was not properly outlined with a positive control, which could determine any experimental flaw. It also did not indicate the type of the extract used. An elevation in oxidative stress and inflammation has been reported in isoproterenol-induced myocardial injury (Kumari et al., 2020; Younis et al., 2020). Therefore, the extract most likely elicits protective effects through its antioxidant and anti-inflammatory properties, as previously reported (Tewtrakul et al., 2015; Suwan et al., 2018). The property of the plant extract may support its traditional use in reducing heart problems (Mekala and Radha, 2015). Further *in vivo* studies are necessary to obtain more conclusive evidence of the protective effects of the extract. Heart function should be examined to measure the extent of improvement due to the extract. Other aspects that can be studied are pathways related to myocardial fibrosis, such as the transforming growth factor-β/Smads (TGF-β/Smads) pathway and other pathways linked to oxidative stress, inflammation, apoptosis, and mitogen-activated protein kinase (MAPK) activation.

Stem extract of *C. sappan* (100 μg/ml) has been found to inhibit phosphodiesterase (PDE) activity in *in vitro*, with ethanol extracts demonstrating greater activity against PDE-1 than hexane and chloroform extracts (Helmi et al., 2020). Although the expression of this enzyme was reported to be elevated in heart failure (Chen et al., 2020), the potential effects of *C. sappan* extract on heart failure have not been studied. Recent evidence suggests that PDE5 and PDE10A inhibition is cardioprotective in patients with systolic heart failure and left ventricular hypertrophy (Lawless et al., 2019; Chen et al., 2020). Inhibition of the enzyme increases the intracellular level of cyclic adenosine monophosphate (cAMP) (Chen et al., 2020), which then boosts Ca\(^{2+}\) influx leading to increased myocardial contractility (Irie et al., 2009). Therefore, the extract should be further studied to explore its potential inhibitory regulation of isoenzymes, which could have beneficial effects by improving heart function. The effects of the extract on myocardial contractile function, intracellular calcium concentration, and cAMP should also be explored.

**Brazilin**

The effects of brazilin on myocardial ischemia/reperfusion (I/R) injury have been investigated through *in vitro* and *ex vivo* models for acute myocardial infarction in humans. In rat cardiomyocytes exposed to hypoxia/reoxygenation (H/R), brazilin (5–50 μM) reduced the release of creatine kinase MB (CK-MB) and lactate dehydrogenase (LDH) in a dose-dependent manner (Table 2). It also decreased H/R-induced apoptosis, observed as a reduction in cleaved caspase 3 (Qi et al., 2021). In the *ex vivo* study, brazilin pretreatment (at 12.5–50 mg/kg intraperitoneally) reduced myocardial infarct size, CK-MB and LDH release, and myocardial apoptosis (at 25 mg/kg) in isolated hearts subjected to I/R injury. It preserved myocardial function by reversing the detrimental effects of I/R on left ventricular (LV) pressure (LVDP), the rate of LV pressure increase (+dp/dt), and the rate of LV pressure reduction (−dp/dt) (Qi et al., 2021). No positive control was adopted in both models. Therefore, comparative protective effects with the brazilin-treated group could not be appreciated. The protective effects of brazilin are believed to be mediated by nuclear factor erythroid 2-related factor 2 (Nrf2), a gene involved in the modulation of...
oxidative stress (Figure 2). Kelch-like ECH-associated protein 1 (Keap1), a substrate adaptor, suppresses Nrf2 transcriptional activity through the formation of a complex between the domains of Nrf2 and Keap1. Upon stimulation of oxidative stress, Nrf2 is dissociated from Keap1 and translocated into the nucleus (Ahmed et al., 2017). Brazilin enhances the activity through the formation of a complex between the domains of Nrf2 and Keap1. Upon stimulation of oxidative stress, Nrf2 is dissociated from Keap1 and translocated into the nucleus (Ahmed et al., 2017). Brazilin enhances the activity of the nuclear factor-κB (NF-κB) and its inflammatory signaling pathway. Blockade of NF-κB improved cardiac function and attenuated cardiac remodeling in a myocardial infarct mouse model (Kawano et al., 2006). Brazilin has also been demonstrated to possess PDE-1 inhibitory activity in vitro (Helmi et al., 2020), leading to an increased level of cAMP, which also functions as a fibrotic response modulator (Delaunay et al., 2019). The inhibition of this enzyme led to a decreased fibrotic response in cardiomyocytes (Chen et al., 2020), which may be useful for the therapeutic management of heart failure. However, further studies are needed to confirm this activity in vivo and to explore other potentially related mechanisms of brazilin, such as myocardial protein synthesis, fibrosis, autophagy, and hypertrophic signaling.

### Sappanone A

Two studies have investigated the effects of sappanone A on myocardial I/R injury (Shi et al., 2020b; Jo et al., 2020). In rats with ligated left anterior descending coronary artery, oral administration of sappanone A at 50 mg/kg for 5 days starting on the day of ischemia induction, significantly reduced the infarct size, particularly in the distal medial and apical myocardial areas, better than that of curcumin, a positive control (Jo et al., 2020). However, the use of curcumin as the positive control was less

### TABLE 2 | Effects of C. sappan crude extract and its bioactive compounds on myocardial parameters.

| Model | Dose and duration of bioactive compounds | Effects on cardiac parameters |
|-------|------------------------------------------|-------------------------------|
|        |                                          | Function | Structure | Injury index | Infarct size |
| Nugraheni and Saputri, (2017) | I/R (in vivo) | Crude extract (50, 100 and 200 mg/kg) pretreatment for 30 days | - | ↔ HW/BW; All doses | ↓ Infarct size |
|        |                                          |         |          |              |              |
| Shi et al. (2020b) | I/R (ex vivo) | Brazilin (12.5–50 mg/kg, ip) treatment for 1 h | ↔ HR | ↔ LVDP, +dp/dt, –dp/dt, LVDP | ↓ Infarct size |
| Zhao et al. (2006) | Ex vivo | Brazilein (0.4–10 mM) concurrently for 2 h | ↔ contractility, ↔ HR | - | - |
| Shi et al. (2020a) | I/R (ex vivo) | Sappanone A (20 mg/kg, ip) pretreatment for 1 h | ↔ HR | ↔ LVDP, +dp/dt, –dp/dt, LVDP | ↓ Infarct size |
| Jo et al. (2020) | LAD-induced I/R (in vivo) | Sappanone A (50 mg/kg, po) for 5 days (day 0 to day 4 post-I/R) | ↔ Cardiac structure | ↓ Infarct size |
| Qi et al. (2021) | H/R in cardiomyocytes | Brazilin (5–50 µM) pretreatment for 1 h | ↓ Inflammatory cells in PM and apex | ↓ AST |
| Shi et al. (2020a) | H/R in cardiomyocytes | Sappanone A (5–50 µM) pretreatment for 1 h | - | ↓ cell viability |

**Abbreviations:** AST, Aspartate transaminase; CO, cardiac output; CK-MB, creatine kinase MB; cTn1, cardiac troponin 1; +dp/dt, rate of the rise in left ventricular pressure; –dp/dt, rate of the fall of left ventricular pressure; E′, early relaxation velocity on tissue Doppler; E/A, the ratio of the early (E) to late (A) ventricular filling velocities; E/E′, ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity; FS, fractional shortening; HR, heart rate; ip, intraperitoneum; H/R, hypoxia/reoxygenation; HW/BW, heart weight to body weight ratio; I/R, ischemia/reperfusion; LAD, ligation of the left anterior descending coronary artery; LDH, lactate dehydrogenase; LVDP, Left ventricular developed pressure; po, oral; PM, papillary muscle; SV, stroke volume; ↔, no change; ↓, increased; ____, reduced.
appropriate since it is not used clinically for heart diseases. In addition, histological analysis revealed that the homoisoavonoid treatment diminished inflammatory cell infiltration, with larger effects on lymphocytes in all medial myocardial and epicardial regions. It also reduced fibrosis in papillary muscle, comparable to curcumin (Jo et al., 2020). Furthermore, the results indicated that sappanone A reduced fibrosis in the papillary muscle. The positive effects of the compound were supported by decreases in serum CK-MB, LDH, and aspartate transaminase (Jo et al., 2020), indicators of myocardial injury. Shi et al. (2020b) demonstrated that intraperitoneal administration of sappanone A at 20 mg/kg per hour prior to I/R injury induction exerted protective effects in isolated Langendorff hearts, as indicated by a reduction in the myocardial infarct size and a release of myocardial enzymes (CK-MB and LDH). The cardioprotective effects of the compound could also be attributable to its anti-inflammatory properties (Wang et al., 2021).

Both the above studies demonstrated that sappanone A improved cardiac function after I/R (Jo et al., 2020; Shi et al., 2020b) (Table 2). LVDP, +dp/dt, and −dp/dt increased in the sappanone A-treated group, as measured in isolated hearts (Shi et al., 2020b), suggesting improvement in LV function. In the in vivo study (Jo et al., 2020), sappanone A did not significantly affect LV fractional shortening (FS) or the ejection fraction (EF), two indicators of LV systolic function, although a tendency for a reversal effect was observed. Tissue Doppler imaging revealed that the treatment improved the early relaxation velocity (E′), an indicator of LV diastolic function, on day 1 post-I/R induction but not on day 4. Moreover, positive effects of the compound on the ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity (E/E′), another indicator of LV diastolic function, were noted on both day 1 and day 4 (Jo et al., 2020). The findings of these studies strongly suggest that sappanone A from C. sappan affords better...
cardioprotection in the early stage of myocardial infarction, resulting in the mitigation of LV dysfunction. It is possible that the preservation of the cardiac function by sappanone A due to its inhibitory effect on fibrosis in the heart (Jo et al., 2020). However, the detailed mechanisms of the antifibrotic property of the compound have yet to be studied.

Treatment with sappanone A resulted in the alteration of the mRNA expression of 2020 genes, including 66 proinflammatory-related genes believed to be involved in myocardial infarction. Sappanone A may exert positive effects by restoring the genes involved in inflammatory responses. It downregulates the expression of the proinflammatory genes Tgfb1, Tgfb2, Tnfrsf1a, Il18, Pik3cd, Cd4, and Cdc8a, as well as the apoptotic gene Casp3, which are activated by myocardial infarction (Jo et al., 2020). In cardiomyocytes, sappanone A alleviated H/R-induced injury by inhibiting mitochondrial apoptosis, observed as repressed caspase-3 and caspase-9 cleavage, leading to increased cell viability. The compound also mitigated mitochondrial permeability transition pore (mPTP) opening and transmembrane potential (Δψm) release (Shi et al., 2020a), possibly because of its antioxidant and anti-inflammatory activities (Figure 2) that reduce reactive oxygen species (ROS), which stimulate the opening of mPTPs, increase the permeability of mitochondria, and subsequently rupture the organelles (Zhang et al., 2016). Sappanone A is reported to provide cardioprotection against I/R-induced injury by activating the phosphatidylinositol 3-kinase/protein kinase B/glycogen synthase kinase-3 against I/R-induced injury by activating the phosphatidylinositol protein that regulates antioxidant proteins (Tu et al., 2019). Of the adrenal glands (Kang et al., 2019). The PI3K/Akt/GSK-3β pathway has been reported in PC-12 cells obtained from pheochromocytomas (Kanai et al., 2020), suggesting that sappanone A on the activation of Akt and Gsk-3β have also been reported in PC-12 cells obtained from pheochromocytomas of the adrenal glands (Kang et al., 2019). The PI3K/Akt/GSK-3β signaling pathway is activated by an increased ROS level which is partly due to the increased activity of xanthine oxidase (Figure 2). The activation of the pathway leads to inhibition of mitochondrial apoptosis and mPTP opening, resulting in decreased cardiac damage. Sappanone A also activates the Keap1/Nrf2 signaling pathway (Shi et al., 2020b), which is one of the crucial signaling pathways controlling the activity of Nrf2, a protein that regulates antioxidant proteins (Tu et al., 2019). Together, these effects suggest that sappanone A could be a potential therapeutic agent for alleviating myocardial I/R injury by targeting mitochondria through the mitigation of the inflammatory, oxidative stress, and apoptosis signaling pathways.

**Brazilein**

At 0.4–10 mM concentrations, brazilein had a concentration-dependent cardiotoxic effect with negligible impacts on coronary perfusion and heart rate in normal isolated guinea pig hearts, better than its positive control, noradrenaline (30 μM); this effect may not involve the stimulation of the β-adrenoceptor because the addition of propranolol, a β-adrenoceptor blocker, had no effect (Zhao et al., 2006). However, the concentrations used were larger than the ones proposed (30–50 μM) for in vitro studies (Heinrich et al., 2020). It is quite difficult to translate high concentrations of pure compounds employed in vitro for a therapeutic use in humans, as it may pose toxicity.

Brazilein inhibited Na⁺/K⁺-ATPase (the sodium–potassium pump) (Figure 2) but this effect was not modified by increasing concentrations of potassium (Zhao et al., 2006). This finding suggests that the inhibitory effect of brazilein may not be associated with its binding to E2P (Zhao et al., 2006), which in turn prevents E2P from binding to potassium resulting in the inhibition of the sodium–potassium pump. High concentrations of potassium can reverse the inhibitory effects of cardiac glycosides on the sodium–potassium pump and promote the dissociation of E2P and inhibitors (Kanai et al., 2020), suggesting that brazilein has a different mechanism from that of cardiac glycosides. The sodium–potassium pump indirectly regulates the intracellular calcium level in the heart. Its inhibition elevates the myocardial intracellular calcium level by decreasing the calcium efflux through the Na⁺/Ca⁺² exchanger, which then increases myocardial contractility (Salim et al., 2020). Brazilein may modulate other calcium regulators, such as ryanodine receptor 2 (RyR2), L-type calcium channel, and sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA). It was reported that the vasoconstriction effects of brazilein depend on the extracellular calcium level (Shen et al., 2008). In terms of its toxicity, brazilein (at 4–48 mg/kg) is less likely to cause cardiac arrhythmias than deslanoside (at 400–560 μg/kg), a sodium–potassium pump inhibitor (Zhao et al., 2006), implying a higher therapeutic index for the former. Therefore, brazilein has the potential to be developed as an inotropic drug with Na⁺/K⁺-ATPase inhibition as the therapeutic target. Its effects on other calcium regulatory proteins—Na⁺/Ca⁺² exchanger, RyR2, and SERCA—should also be studied.

**Other Compounds**

The bioactive compounds, neoprotosappanin, protosappanin A, protosappanin A dimethyl acetal, protosappanin E-2, neosappanone A, sappanol, deoxysappanone B, sappanone B, and sappanchalcone isolated from C. sappan extract and its methanol ethyl acetate fraction have been reported to possess xanthine oxidase-inhibiting activity (Nguyen et al., 2004, 2005), which could be beneficial in alleviating myocardial injury. Among these compounds, sappanchalcone demonstrated the most potent activity, comparable to allopurinol (Nguyen et al., 2004, 2005). The protective effect is most likely due to these compounds’ antioxidant properties. Previous research indicated that some of these compounds possess antioxidant properties (Sasaki et al., 2007). However, no studies investigating these compounds have considered their effects on the heart. The serum xanthine oxidase level is reported to be elevated in patients with myocardial infarction (Ali et al., 2014). This enzyme produces abundant ROS during cardiac ischemia (Figure 2), which causes further damage to the heart (Bagheri et al., 2016). A meta-analysis of randomized clinical trials reported that purine-like xanthine oxidase inhibitors, such as allopurinol, reduced in the incidence of adverse cardiovascular outcomes (Bredemeier et al., 2020).
et al., 2018). Further investigations of C. sappan phytochemicals should be undertaken to explore their potential cardioprotective effects that could be attributed to xanthine oxidase inhibition, such as the expression of extracellular matrix proteins (collagen and fibronectin), growth factors, and inflammatory and oxidative stress biomarkers.

Numerous studies have demonstrated that C. sappan extract and its bioactive compounds can reduce heart transplant and allograft rejection. The extract itself was reported to reduce cell ultrastructural damage and pathological morphology in transplanted hearts by reducing perforin mRNA expression (Zhou et al., 2003), whereas the ethyl acetate extract decreased granzyme B (GrB) mRNA expression, comparable to its positive control, cyclosporine A (Zheng et al., 2008). However, both studies lacked a negative control, a group without any treatment for a comparison. Both perforin and GrB are involved in target cell apoptosis (Voskoboinik et al., 2015), indicating that the compounds exert their beneficial effects by diminishing cell apoptosis. The aqueous extract also suppresses T-lymphocyte activation and increases CD4+ CD25+ T cells (Yu et al., 2004), diminishing cell apoptosis. The extract itself was reported to reduce cell ultrastructural damage and pathological morphology in transplanted hearts by reducing perforin mRNA expression (Zhou et al., 2003), whereas the ethyl acetate extract decreased granzyme B (GrB) mRNA expression, comparable to its positive control, cyclosporine A (Zheng et al., 2008). However, both studies lacked a negative control, a group without any treatment for a comparison. Both perforin and GrB are involved in target cell apoptosis (Voskoboinik et al., 2015), indicating that the compounds exert their beneficial effects by diminishing cell apoptosis. The aqueous extract also suppresses T-lymphocyte activation and increases CD4+ CD25+ T cells (Yu et al., 2004; Li et al., 2015), contributing to its immunosuppressive effect, hence reducing the rejection rate. The cardioprotective effects could also be attributed to the presence of protosappanin A. At a dose of 25 mg/kg, the compound prolonged heart allograft survival and decreased pathological damage, leading to reduced graft rejection, comparable to cyclosporine A (Wu et al., 2008). The antirejection property of the compound may be due to the diminished inflammation, observed as reduced mRNA expression of NF-kB; suppressed immune response, indicated by decreased interferon-gamma (IFN-γ), interferon-gamma-inducible protein 10 (IP10), and the CD4+/CD8+ ratio; and lower levels of apoptosis, demonstrated by downregulated GrB and perforin mRNA expression (Wu et al., 2008; Wu et al., 2010). In conclusion, protosappanin A may promote immunosuppression in recipients by targeting the graft’s T cells through inhibition of the NF-kB pathway activation and apoptosis. Further studies should be undertaken to extensively investigate the antirejection effects of protosappanin A, which has the potential to be employed clinically.

**EFFECTS ON VASCULAR FUNCTION AND INJURY**

**Caesalpinia sappan Extract**

Endothelial dysfunction promotes vascular injury by disrupting vascular tone and redox balance, and activating inflammatory responses (Sun et al., 2020). Studies investigating the effects of C. sappan extract on vascular function and injury are still lacking, although the extract was demonstrated to protect against brain I/R injury (Wan et al., 2019).

Caesalpinia sappan crude extract (10 and 30 µg/ml) had a vasorelaxant effect on precontracted intact rat aortic rings but not denuded rings (Hu et al., 2003). The effects were reduced by N(G)-nitro-l-arginine methyl ester (l-NAME), a nitric oxide synthase (NOS) inhibitor. However, at higher concentrations of the extract (100 µg/ml), the vasorelaxant effect was not affected by denudation or l-NAME treatment (Xie et al., 2000), implying that the effects are both dependent on and independent of the functional endothelium. It is possible that at higher concentrations, the extract may exert its effects by directly stimulating smooth muscle cells rather than by activating the release of nitric oxide, which is primarily synthesized in the endothelium (Cyr et al., 2020). A drawback of the studies (Xie et al., 2000; Hu et al., 2003) was no validated identification of the dried heartwood sappanwood which was obtained from a local store. Therefore, reproducibility of the findings could be questioned.

**Brazilin**

Similar to the crude extract, brazilin exhibited vasorelaxant properties that were dependent on the endothelium at lower concentrations (30 µM) (Hu et al., 2003) but independent of the endothelium at higher concentrations (100 µM) in precontracted intact rat aortic rings (Xie et al., 2000; Yan et al., 2015). However, Hu et al. (2003) demonstrated that the effect of brazilin was only endothelium-dependent and suggested that the relaxing property of the extract at higher concentrations was possibly attributable to the presence of brazilin, which was similar to histamine (50 µM). In the endothelium-dependent vasorelaxation mechanism, brazilin may induce relaxation by decreasing the influx of Ca2+ through L-type calcium channels and its release from the sarcoplasmic reticulum via the compound’s effects on RyR2 and inositol trisphosphate (IP3) receptors, thus enhancing SERCA activity (Yan et al., 2015), but unfortunately these effects could not be compared with a positive control which was not included in the study (Figure 3). The vasodilating effect of the compound is notably deterred by l-NAME and hemoglobin (a nitric oxide scavenger), indicating that its effect involves the presence of nitric oxide (Hu et al., 2003; Yan et al., 2015). This is further confirmed by its positive effects on nitric oxide synthesis via activation of endothelial NOS (eNOS) (Hu et al., 2003). Following this activation, cyclic guanosine monophosphate (cGMP) is generated from guanosine-5′-triphosphate (GTP) by the action of soluble guanylate cyclase (sGC) in vascular smooth muscle. Brazilin is reported to augment the accumulation of sGC in the rat aorta, and pretreatment with methylene blue, an sGC inhibitor, markedly diminishes the vasodilating effect of brazilin, suggesting a crucial role of sGC in brazilin’s mechanisms of action (Hu et al., 2003; Yan et al., 2015). The increase in cGMP level would enhance the level of cAMP, causing a decline in Ca2+ level and finally subsiding the constriction of the blood vessels.

The vasorelaxant effect of brazilin may also involve prostaglandin synthesis, as suggested by its reduced effect with indomethacin, a cyclooxygenase inhibitor, as well as its inhibition of extracellular signal-regulated kinase (ERK) and myosin light chain (MLC) activation (Yan et al., 2015). Cyclooxygenase is an enzyme that synthesizes prostaglandin from arachidonic acid. Prostaglandin itself is a strong vasodilator, which is also converted into products such as thromboxane, a vasoconstrictor, and prostacyclin, a vasodilator (Rouzer and Marnett, 2020). Therefore, brazilin may augment the
production of prostaglandin which then promotes vasodilation. By contrast, ERK has an inhibitory effect on eNOS, impairing vasodilation, and MLC causes vasocontraction (Figure 3). Thus, the activation of ERK and MLC plays a crucial role in vascular smooth muscle cell contractile function (Roberts, 2012; Liu and Khalil, 2018). However, it was postulated that the brazilin vasodilatory effect is not mediated by Ca$^{2+}$-dependent K$^+$ channel activation (Yan et al., 2015), which is responsible for blood vessel dilation (Hasan and Jaggar, 2018). All these results suggest that brazilin has the potential to act as an agent that promotes vasorelaxation and as a calcium antagonist. However, further studies should explore this potential in depth, especially through in vivo investigations in hypertensive animals to ascertain its effects on blood pressure. Future studies should also focus on the ability of brazilin to block calcium channels, and well-designed studies are necessary to compare the activity of brazilin with that of existing calcium channel blockers. Through further research, brazilin has the potential to be developed as a blood pressure-lowering agent.

Brazilin pretreatment (at 50 and 100 $\mu$M) also ameliorates vascular inflammation and oxidative stress induced by high glucose in human umbilical vein endothelial cells (HUVEC). High glucose enhances the formation of cell adhesion molecules, i.e., intercellular (ICAM) and vascular adhesion molecules (VCAM) in the cells, which are reduced by brazilin (Jayakumar et al., 2014) (Figure 3). High glucose promotes NF-κB activation, which mediates the inflammatory response by upregulating cell surface expression of adhesion molecules (Morigi et al., 1998). The beneficial effects of the compound are believed to be mediated by its ability to inhibit the activation of ERK, NF-κB, and eNOS triggered by exposure to high glucose (Jayakumar et al., 2014). These findings suggest that brazilin may be useful in the management of diabetes involving microangiopathy. C. sappan crude extract has been used to control diabetes in folk medicines (Mekala and Radha, 2015). However, more in-depth research should be carried out for conclusive evidence. Brazilin was also reported to be protective against renal I/R injury by suppressing the NF-κB signaling pathway (Jia et al., 2016).

Platelets are a blood component involved in blood coagulation in response to bleeding due to vascular injury. Brazilin exerted antiplatelet activity in mouse platelets in vitro (Ji et al., 2019), whereas Chang et al. (2013) reported brazilin’s ability to stimulate platelet aggregation in human platelets in vitro. The discrepancy in these findings could be due to the difference in the platelet source species. Further study is needed to clarify this issue. Chang et al. (2013) demonstrated that brazilin potentiated collagen-induced platelet aggregation in vitro at lower concentrations (1–10 $\mu$M), whereas at higher concentrations (20–50 $\mu$M), it had a direct effect on platelet aggregation. This property
associates with its traditional use in treating bleeding gums and uterine bleeding (Mekala and Radha, 2015). The addition of yohimbine (an adrenoceptor antagonist) and a thrombin protease-activated receptor antagonist had no significant effect on brazilen’s properties. However, the addition of caffeic acid phenethyl ester (a collagen receptor antagonist) reduced platelet aggregation. These observations suggest that the platelet-activating property of brazilen does not involve adrenoceptor or protease-activated receptor stimulation; instead, it may be due to the direct activation of collagen receptors. By contrast, it was suggested that brazilen exerts its antiplatelet activity by stimulating protease-activated receptor 4 (Ji et al., 2019). Brazilen is a promising candidate for further research on its potential as a collagen receptor agonist. This property is beneficial in the clinical management of vascular injury that involves blood coagulation.

Other favorable properties of brazilen are the prevention of vascular smooth muscle cell migration and proliferation which was demonstrated in an in vitro study (Guo et al., 2013). These vascular events can enhance vascular diseases, such as restenosis and atherosclerosis (Louis and Zahradka, 2010). Brazilen (at 3, 10, and 30 µM) inhibited platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell proliferation by inducing G0/G1 cell cycle arrest without affecting cell viability. It also downregulated G0/G1 phase regulatory proteins, namely cyclin E and cyclin-dependent kinase 2 (CDK2), and upregulated p27, but it had no effect on cyclin D. Cyclins D and E, and CDK2 are positive regulators for the G0/G1 transition, whereas p27 is a negative regulator (Guo et al., 2013). Inhibition of cell migration by brazilen is associated with reduced cellular expression of adhesion molecules (ICAM-1 and VCAM-1) and matrix metalloproteinase-9 (MMP-9). MMPs are mediators of the progression of vascular lesions (Suh et al., 2006). The inhibitory effects of brazilen on both cell proliferation and migration are believed to be linked to the suppression of PDGF receptor β activation, thereby preventing the signaling cascade and leading to the inhibition of ERK1/2, Src, and Akt activation (Guo et al., 2013). ERK1/2 activation promotes cell growth and migration, events that are important in the commencement and development of vascular lesions (Suh et al., 2006), whereas the activation of Src kinases and PI3K/Akt are associated with various cellular events, such as cellular differentiation, proliferation, and cytoskeletal reorganization (Sayeski and Ali, 2003; Zhang et al., 2020). Despite its good findings, a shortcoming of the study (Guo et al., 2013) is an absence of a positive control group. Taken together, brazilen has the potential to prevent atherosclerosis and restenosis, and these effects warrant further in vivo studies.

**Brazilein**

Different from brazilen, its oxidized form, brazilein (at 100 µM), promotes vasoconstriction in rat thoracic aortic rings, comparable to caffeine (20 mM) but lesser than phenylephrine (10 µM). The effect is not endothelial-dependent and does not involve the stimulation of α- and β-adrenoceptors, muscarinic receptors, or angiotensin II type 1 receptors (Shen et al., 2008). However, its effects are significantly weakened by the addition of nisodipine and diltiazem (L-type Ca2+ channel blockers) and pinacidil (a potassium channel opener), indicating that the vasoconstriction effect of brazilein is dependent on Ca2+ influx (Shen et al., 2008). Extracellular Ca2+ entry is required for the contraction of vascular smooth muscle cells. Pinacidil increased potassium efflux, leading to hyperpolarization, which then reduced Ca2+ influx (Tinker et al., 2018) (Figure 3). The reduction in Ca2+ entry diminishes the effects of brazilein. The effect of brazilein on blood vessels was not associated with the activation of protein kinase C (PKC) or IP3 receptor, demonstrated by the lack of effect observed with the addition of their respective inhibitors (Shen et al., 2008). However, the co-administration of inhibitors of MLCK (MLCK), Rho-kinase (ROCK), and ERK decreased the vasoconstriction property of the compound. Collectively, these findings suggest that brazilein most likely exerts vasoconstriction via the activation of the L-type calcium channel and the involvement of ROCK, MLCK, and ERK. More studies, especially in vivo studies, are needed to confirm the effects seen in the in vitro setting.

**Other Compounds**

Few studies to date have investigated other bioactive compounds isolated from C. sappan for their potential role in vascular injury. Hematoxylin (at 10, 30, and 100 µM) from the heartwood also demonstrated vasorelaxant activity in precontracted intact rat aortic rings, but the effects were reduced in denuded rings and these observations were not compared with a positive control (Xie et al., 2000). The effects were also diminished by 1-NAME, suggesting the involvement of nitric oxide in its effect. He et al. (2009) reported vasorelaxant effects of (E)-3-(3,4-dihydroxybenzylidene)-7-hydroxychroman-4-one, sappanone B, and 3-deoxysappanonone B in endothelium-intact and endothelium-denuded aortic rings, suggesting an independent effect of the presence of endothelium (Figure 3). However, the vasorelaxant activity of the compounds was diminished in the presence of an eNOS inhibitor and an sGC inhibitor, indicating that the compounds exerted their effects via the nitric oxide-cGMP pathway (He et al., 2009). Nonetheless, it is not yet confirmed whether these compounds elicit the effect by acting directly or indirectly on the vascular muscarinic receptors. Further studies should be conducted to clarify this. On the other hand, 1-hydroxy-7-methylxanthone, 1,7-dihydroxyxanthone, butein, and sappanone A were demonstrated to significantly inhibit lipopolysaccharide-induced nitric oxide production in vitro (Zhao et al., 2014). A high level of nitric oxide in blood vessels is beneficial because of its vasodilating effect (Kamisah et al., 2017), but its synthesis is also enhanced under oxidative stress, which could be harmful because of its ability to form peroxynitrite radicals (Kamisah et al., 2016). Therefore, the ability of these C. sappan phytochemicals to suppress nitric oxide production following exposure to stress is advantageous.

Sappanachalone also possesses antiplatelet activity. Other compounds, such as 3-deoxysappanone B, caesalpin J. epicaesarpin J, episyringaresinol, methylsappanol, and protosappanin A isolated from the plant were also screened and found to have negligible effects (Ji et al., 2019). However, the possible mechanism of action of the...
sappanchalcone was not elucidated in the study. The compound may manifest its property via the same mechanism as brazilin, but this postulation has yet to be confirmed. Its effects on other clotting factors, such as prothrombin, activated factor IX, and plasminogen activator, should also be studied.

CONCLUSION AND DIRECTIONS FOR FUTURE STUDY

This review shows that C. sappan Linn. contains many bioactive compounds, such as brazilin, brazilein, and sappanone A, that should be further studied and developed as potential candidates for treating cardiovascular problems, particularly myocardial infarction, cardiac remodeling, and hypertension. However, well-designed studies with appropriate controls (negative and positive) and a good range of doses to date are still at a preliminary stage. In vivo studies to confirm the activities seen in ex vivo and in vitro studies are still lacking. The effects of C. sappan bioactive compounds on myocardial calcium handling proteins, mitochondrial function, PI3K/Akt/mammalian target of rapamycin (mTOR), and cellular mechanotransduction, as well as the renin–angiotensin–aldosterone system, should be explored to better understand their mechanistic pathways. Certain genes involved in the pathogenesis of hypertension—Alb, Chrm2, Xpir1, Kcnq1, Slc5a7, Kcnh1, Ache, Crf1l and Gαr2—should also be studied. To progress to clinical trials, the safety of the compounds for administration to humans should also be determined.

AUTHOR CONTRIBUTIONS

MS and YK wrote and revised the manuscript. RS contributed to manuscript writing and editing.

FUNDING

This research was supported by the Faculty of Medicine, Universiti Kebangsaan Malaysia Matching Grant (FF-2019-480 and FF-2019–480/1) and University Research Grant from the Ministry of Research and Technology of the Republic of Indonesia (Number: 1827/UN6.3.1/LT/2020).

REFERENCES

Ahmed, S. M., Luo, L., Namani, A., Wang, X. J., and Tang, X. (2017). Nrfl2 Signaling Pathway: Pivotal Roles in Inflammation. Biochem. Biophys. Acta Mol. Basis Dis. 1863 (2), 585–597. doi:10.1016/j.bbdis.2016.11.005
Ali, O. S., Abdelgawad, H. M., Mohammed, M. S., and El-Awady, R. R. (2014). Ischemic Heart Diseases in Egypt: Role of Xanthine Oxidase System and Ischemia-Modified Albumin. Heart Vessels 29 (5), 629–637. doi:10.1007/s00380-013-0413-3
Badani, S., Mookoth, S., and B, S. (2004). Caesalpinia Sappan – A Medicinal and Dye Yielding Plant. Indian J. Nat. Prod. Res. 3 (2), 75–82.
Bagheri, F., Khor, V., Alizadeh, A. M., Khalighfard, S., Khodayari, S., and Khodayari, H. (2016). Reactive Oxygen Species-Mediated Cardiac-Reperfusion Injury: Mechanisms and Therapies. Life Sci. 165, 43–55. Elsevier B.V. doi:10.1016/j.lfs.2016.09.013
Bao, H., Zhang, L. L., Liu, Q. Y., Feng, L., Ye, Y., Lu, J. J., et al. (2016). Cytotoxic and Pro-apoptotic Effects of Cassane Diterpenoids from the Seeds of Caesalpinia Sappan in Cancer Cells. Molecules 21 (6), 791. doi:10.3390/molecules21060791
Bredemeier, M., Lopes, L. M., Eisenreich, M. A., Hickmann, S., Bongiorno, G. K., d’Avila, R., et al. (2018). Xanthine Oxidase Inhibitors for Prevention of Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Cardiovasc. Disord. 18 (1), 24–11. doi:10.1186/s12872-018-0757-9
Chang, Y., Huang, S. K., Lu, W. J., Chung, C. L., Chen, W. L., Lu, S. H., et al. (2013). Brazilin Isolated from Caesalpinia Sappan L. Acts as a Novel Collagen Receptor Agonist in Human Platelets. J. Biomed. Sci. 20 (1), 4. doi:10.1186/1423-0127-20-4
Chellapann, D. R., Purushothaman, A. K., and Brindha, P. (2017). Gastroprotective Potential of Hydro-Alcoholic Extract of Pattanga (Caesalpinia Sappan Linn.). J. Ethnopharmacol. 197, 294–305. doi:10.1016/j.jep.2016.07.081
Chen, S., Zhang, Y., Lighthouse, J. K., Mickelsen, D. M., Wu, J., Yao, P., et al. (2020). A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction. Circulation 141 (3), 217–233. doi:10.1161/CIRCULATIONAHA.119.042178
Choo, Y. Y., Tran, P. T., Min, B. S., Kim, O., Nguyen, H. D., Kwon, S. H., et al. (2017). Sappanone A Inhibits RANKL-Induced Osteoclastogenesis in BMMs and Prevents Inflammation-Mediated Bone Loss. Int. Immunopharmacol. 52, 230–237. doi:10.1016/j.intimp.2017.09.018
Cuong, T. D., Hung, T. M., Kim, J. C., Kim, E. H., Woo, M. H., Choi, J. S., et al. (2012). Phenolic Compounds from Caesalpinia Sappan Heartwood and Their Anti-inflammatory Activity. J. Nat. Prod. 75 (12), 2069–2075. doi:10.1021/np3003673
Cyr, A. R., Huckaby, L. V., Shiva, S. S., and Zuckerbraun, B. S. (2020). Nitric Oxide and Endothelial Dysfunction. Crit. Care Clin. 36 (2), 307–321. doi:10.1016/j.ccc.2019.12.009
Dapson, R. W., and Bain, C. L. (2015). Brazilwood, Sappanwood, Brazilin and the Red Dye Brazilian: From Textile Dyeng and Folk Medicine to Biological Staining and Musical Instruments. Biotech. Histochem. 90 (6), 401–423. doi:10.3109/10520295.2015.1021080
Delmauy, M., Osman, H., Kaiser, S., and Diviani, D. (2019). The Role of Cyclic AMP Signaling in Cardiac Fibrosis. Cells 9 (1), 69. doi:10.3390/cells9010069
Do, T. L. (2001). Vietnamese Medicinal Plants. Hanoi: Medicine Publisher.
Fu, L. C., Huang, X. A., Lai, Z. Y., Hu, Y. J., Liu, H. J., and Cai, X. L. (2008). A New 3-benzylchrylom Derivative from Sappan Lignum (Caesalpinia Sappan). Molecules 13 (8), 1923–1930. doi:10.3390/molecules13081923
G., A., J.A., A., R., Usha Raja, U. R. N., and Padmalatha, C. (2017). Toxicological Studies of Caesalpinia Sappan wood Derived Dye in Wister Albino Rats. Food Sci. Hum. Wellness 6 (1), 34–38. doi:10.1016/j.fshw.2016.10.004
Guo, J., Li, L., Wu, Y. J., Yan, Y., Xu, X. N., Wang, S. B., et al. (2013). Inhibitory Effects of Brazilein on the Vascular Smooth Muscle Cell Proliferation and Migration Induced by PDGF-BB. Am. J. Chin. Med. 41 (6), 1283–1296. doi:10.1142/S0129049713500869
Hadebe, N., Cour, M., and Lecour, S. (2018). The SAFE Pathway for Cardioprotection: Is This a Promising Target? Basic Res. Cardiol. 113 (2), 9. doi:10.1007/s00395-018-0670-5
Hasan, R., and Jaggar, J. H. (2018). KV Channel Trafficking and Control of Vascular Tone. Microcirculation 25 (1), 1–11. doi:10.1111/mic.12418
He, W., Fang, T., Zhang, K., and Tu, P. (2009). [Vasoconstriction Effects of Homoisoflavonoids from Caesalpinia Sappan in Rat Thoracic Aortic Rings]. Zhongguo Zhong Yao Za Zhi 34 (6), 731–734.
Heinrich, M., Appendino, G., Effert, T., Fürst, R., Izzo, A. A., Kayser, O., et al. (2020). Best Practice in Research - Overcoming Common Challenges in Phytopharmacological Research. J. Ethnopharmacol. 246, 112230. doi:10.1016/j.jep.2019.112230
Helmi, N., Falhrudin, A., Sudarmanto, B. S. A., and Ikawati, Z. (2020). In Vitro and In Silico Studies of Secang wood (Caesalpinia Sappan L) Extracts and Brazilin as Natural Phosphodiesterase-1 (PDE1) Inhibitor for Herbal Cognitive...
Enhancer Development. Res. Jour. Pharm. Technol. 13 (5), 2269–2274. doi:10.3958/0974-360X.2020.00409.6

Hsu, C. M., Kang, J. J., Lee, C. C., Li, C. H., Liao, J. W., and Cheng, Y. W. (2003). Induction of Vasorelaxation through Activation of Nitric Oxide Synthase in Endothelial Cells by Brazilian. Eur. J. Pharmacol. 468 (1), 37–45. doi:10.1016/S0014-2990(03)01639-X

Hung, T. M., Hai, N. X., Nhan, N. T., Quang, T. T., Quan, T. L., Cuong, T. D., et al. (2013). Cytotoxic Activity of New Phenolic Compounds from Vietnamese Caesalpinia Sappan. Biosci. Biotechnol. Biochem. 77 (12), 2378–2382. doi:10.1271/bbb.130493

Irie, K., Sato, T., Tanaka, I., Nakajima, J., Kawaguchi, M., and Himi, T. (2009).

Jayakumar, T., Chang, C. C., Lin, S. L., Huang, Y. K., Hu, C. M., Elizebeth, A. R., Leong, D. P., Joseph, P. G., McKee, M., Anand, S. S., Teo, K. K., Schwalm, J. D., et al. (2015). Antiinflammatory and Antiproliferative Catechins from Caesalpinia Sappan. J. Nat. Prod. 78 (10), 2364–2371. doi:10.1021/acs.jnatprod.5b00317

Kamisah, Y., Ang, S. M., Othman, F., Nurul-Iman, B. S., and Qodriyah, H. M. (2012). Prevents Hypertension and Cardiac Damage in Rats. Exp. Clin. Cardiol. 17, e75–85.

Kang, C., Gao, J., Xu, F., and Wang, L. (2019). Reducing the Global burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ. Res. 121 (6), 695–710. doi:10.1161/CIRCRESAHA.117.311849

Li, C., Zhang, H., Gao, D., Ma, Q., Li, Z., Dai, J., et al. (2015). Aqueous Extract of Caesalpinia Sappan Decreolates Allograft Rejection by Inducing Balance between CD4+ CD25+ T Cells and Th17 Cells. Int. J. Clin. Exp. Med. 8 (5), 7107–7115.

Li, L. M., Fu, J. X., and Song, X. Q. (2020). Complete Plasmin Sequence of Caesalpinia Sappan Linnaeus, a Dyestuff and Medicinal Species. Mitochondriona DNA B Resour. 5 (3), 2535–2536. doi:10.1080/23802359.2020.1778579

Li, Z., and Khalil, R. A. (2018). Evolving Mechanisms of Vasomotor Smooth Muscle Contraction Highlight Key Targets in Vascular Disease. Biochem. Pharmacol. 153, 91–122. doi:10.1016/j.bcp.2018.02.012

Louis, S. F., and Zahradka, P. (2010). Vascular Smooth Muscle Cell Motility: From Migration to Invasion. Exp. Clin. Cardiol. 15, e75–85.

Ma, G., Wu, H., Chen, D., Zhu, N., Zhu, Y., Sun, Z., et al. (2015). Antimalarial and Antiproliferative Cassane Diterpenes of Caesalpinia Sappan. J. Nat. Prod. 78 (10), 2364–2371. doi:10.1021/acs.jnatprod.5b00317

Mekala, K., and Radha, R. (2015). A Review on Sappan Wood-A Therapeutic Dye Yielding Tree. Res. Jour. Pharm. Pharmac. 7 (4), 227–231. doi:10.5958/0975-4385.2015.00035.7

Min, B. S., Cuong, T. D., Hung, T. M., Min, B. K., Shin, B. S., and Moo, H. M. (2012). Compounds from the Heartwood of Caesalpinia Sappan and Their Anti-inflammatory Activity. Biorg. Med. Chem. Lett. 22 (24), 7436–7439. doi:10.1016/j.bmcl.2012.10.050

Mingi, M., Angioletti, S., Imberti, B., Donadelli, R., Micheletti, G., Figliuzzi, M., et al. (1998). Leukocyte-endothelial Interaction Is Augmented by High Glucose Concentrations and Hyperglycemia in a NF-kB-dependent Fashion. J. Clin. Invest. 101 (9), 1905–1915. doi:10.1172/JCI656

Mueller, M., Weinmann, D., Toegel, S., Holzer, W., Unger, F. M., and Viernstein, H. (2016). Compounds from Caesalpinia Sappan with Anti-inflammatory Properties in Macrophages and Chondrocytes. Food Funct. 7 (3), 1671–1679. doi:10.1039/c6fo01256b

Nguyen, M. T., Awale, S., Tezuka, Y., Tran, Q. L., and Kadota, S. (2005). Xanthine Oxidase Inhibitors from the Heartwood of Vietnamese Caesalpinia Sappan. J. Pharm. Bull. (Tokyo) 53 (8), 984–988. doi:10.1248/jpb.53.984

Nguyen, M. T. T., Awale, S., Tezuka, Y., Tran, Q. L., and Kadota, S. (2004). Neosappanone A, a Xanthine Oxidase (XO) Inhibitory Dimeric Methanobenzoxococine with a New Carbon Skeleton from Caesalpinia Sappan. Tetrahedron Lett. 45 (46), 8519–8522. doi:10.1016/j.tetlet.2004.09.107

N., M., Krishnakumar, S., Kumar, S. R., and Surendar, K. K. (2014). Caesalpinia Sappan L.: Comprehensive Review on Seed Source Variation and Storability. pgt 3 (2), 11–21. doi:10.5376/pgt.2014.05.0002

Nugrhaeni, K., and Saputri, F. C. (2017). The Effect of Secang Extract (Caesalpinia Sappan Linn) on the Weight and Histology Appearance of White Male Rats’ Hearts Induced by Isoproterenol. Int. J. App Pharm. 9, 59–61. doi:10.22159/ijap.2017v9i3.35

Qi, B., Zhang, X., Yu, H., Bao, Y., Wu, N., and Jia, D. (2021). Brazilin Prevents against Myocardial Ischemia-Reperfusion Injury through the Modulation of Nrf2 via the PKC Beta Signaling Pathway. Ann. Transl. Med. 9 (4), 312. doi:10.21037/atm-20-4414

Roberts, R. E. (2012). The Extracellular Signal-Regulated Kinase (ERK) Pathway: A Potential Therapeutic Target in Hypertension. J. Exp. Pharmacol. 4, 77–83. doi:10.2147/jep.s28907

Routier, C. A., and Marnett, L. J. (2020). Structural and Chemical Biology of the Interactions of Cyclooxygenase with Substates and Non-steroidal Anti-inflammatory Drugs. Chem. Rev. 120 (15), 7592–7641. doi:10.1021/acs.chemrev.0c00215

Salim, S. M., Yunos, N. M., Jauri, M. H., and Kamisah, Y. (2020). Cardiotonic Effects of Cardiac Glycosides from Plants of Apocynaceae Family. Chula. Med. J. 64 (4), 449–456. doi:10.14456/cmj.2020.58

Sasaki, Y., Hosokawa, T., Nagai, M., and Nagumo, S. (2007). In Vitro study for Inhibition of NO Production about Constituents of Sappan lignum. Biol. Pharm. Bull. 30 (1), 193–196. doi:10.1248/bpb.30.193

Sasaki, Y., Suzuki, M., Matsumoto, T., Hosokawa, T., Kobayashi, T., Kamata, K., et al. (2010). Vasorelaxant Activity of Sappan lignum Constituents and Extracts on Rat Aorta and Mesenteric Artery. Biol. Pharm. Bull. 33 (9), 1555–1560. doi:10.1248/bpb.33.1555

Syamsunarno et al.
Switch through Repression of the PI3K/Akt/mTOR Pathway. Histochem. Cel. Biol. 153 (3), 357–366. doi:10.1007/s00418-020-01847-z
Zhao, J., Zhu, A., Sun, Y., Zhang, W., Zhang, T., Gao, Y., et al. (2020). Beneficial Effects of Sappanone A on Lifespan and Thermotolerance in Caenorhabditis elegans. Eur. J. Pharmacol. 888 (38), 173558. doi:10.1016/j.ejphar.2020.173558
Zhao, M. B., Li, J., Shi, S. P., Cai, C. Q., Tu, P. F., Tang, L., et al. (2014). Two New Phenolic Compounds from the Heartwood of Caesalpinia Sappan L. Molecules 19 (1), 1–8. doi:10.3390/molecules19010001
Zhao, Y. N., Pan, Y., Tao, J. L., Xing, D. M., and Du, L. J. (2006). Study on Cardioactive Effects of Brazilein. Pharmacology 76 (2), 76–83. doi:10.1159/000089721
Zheng, J. X., Zhou, Y. B., and Liu, Y. Z. (2008). [Effect of Ethyl Acetate Extract of Sappan wood on Expression of Myocardial GrB mRNA in Rat Model of Allogeneic Ectopic Cardiac Transplantation]. Zhongguo Zhong Xi Yi Jie He Za Zhi 28 (6), 537–540.
Zheng, J., Zhang, S., Chen, H., Cai, X., Zhang, C., Li, S., et al. (2020). Protosappanin-A and Oleanolic Acid Protect Injured Podocytes from Apoptosis through Inhibition of AKT-mTOR Signaling. Cell Biol. Int. 44 (1), 189–199. doi:10.1002/cbin.11218
Zhou, Y. B., Yao, F. Z., and Han, J. R. (2003). [Effect of Sappan wood on Perforin mRNA Expression in Myocardium of Rats after Allogeneic Cardiac Transplantation]. Zhongguo Zhong Xi Yi Jie He Za Zhi 23 (3), 370–372.
Zhu, N. L., Sun, Z. H., Hu, M. G., Wu, T. Y., Yuan, J. Q., Wu, H. F., et al. (2017). New Cassane Diterpenoids from Caesalpinia Sappan and Their Antiplasmodial Activity. Molecules 22 (10), 1–7. doi:10.3390/molecules22101751

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Syamsunarno, Safitri and Kamisah. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.